Feb. 20 Product Development Quick Takes: Priority Review puts BioMarin on track to score first hemophilia gene therapy approval in U.S.; plus Gilead-CDC, Genfit

BioMarin's hemophilia gene therapy gets Priority Review

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) could become the first company to have a hemophilia gene therapy approved in the U.S. FDA accepted and granted Priority Review to a BLA for valoctocogene roxaparvovec to treat severe hemophilia A, giving the candidate an Aug. 21 PDUFA date. The gene therapy -- which comprises an AAV5 vector delivering Factor VIII --

Read the full 633 word article

How to gain access

Continue reading with a
two-week free trial.